UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Strategy Inc
MSTR
|
+$1.21B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$855M |
| 3 |
Microsoft
MSFT
|
+$810M |
| 4 |
Advanced Micro Devices
AMD
|
+$805M |
| 5 |
Boeing
BA
|
+$739M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$561M |
| 2 |
Amneal Pharmaceuticals
AMRX
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$161M |
| 4 |
Unity
U
|
+$158M |
| 5 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$127M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.49% |
| 2 | Financials | 9.06% |
| 3 | Consumer Discretionary | 7.01% |
| 4 | Healthcare | 6.25% |
| 5 | Industrials | 6.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
8026
Evotec
EVO
$700M
| $15.4K | ﹤0.01% |
3,706
+2,676
| +260% | +$11.2K |
|
8027
AmeriServ Financial
ASRV
$77.9M
| $15.4K | ﹤0.01% |
+5,751
| New | +$16K |
|
|
ACTU
8028
Actuate Therapeutics
ACTU
$27.5M
| $15.4K | ﹤0.01% |
+1,934
| New | +$15.8K |
|
|
QH
8029
Quhuo Limited Class A Ordinary Shares
QH
$15.6K
| $15.4K | ﹤0.01% |
117
+31
| +36% | +$3.97K |
|
8030
Biofrontera
BFRI
$15.7M
| $15.3K | ﹤0.01% |
14,073
+10,974
| +354% | +$10.4K |
|
8031
Moving iMage Technologies
MITQ
$5.35M
| $15.3K | ﹤0.01% |
23,578
+20,491
| +664% | +$12.7K |
|
8032
Usio Inc
USIO
$64.9M
| $15.3K | ﹤0.01% |
10,491
-3,768
| -26% | -$5.34K |
|
|
FWDI
8033
Forward Industries Inc
FWDI
$313M
| $15.2K | ﹤0.01% |
+3,080
| New | +$12.4K |
|
8034
GT Biopharma
GTBP
$11.5M
| $15.2K | ﹤0.01% |
4,996
+1,093
| +28% | +$2.96K |
|
8035
Moleculin Biotech
MBRX
$2.8M
| $15.2K | ﹤0.01% |
+358
| New | +$21.7K |
|
8036
IN8bio
INAB
$9.69M
| $15.1K | ﹤0.01% |
1,962
+1,086
| +124% | +$9.54K |
|
8037
John Hancock International High Dividend ETF
JHID
$11.4M
| $15.1K | ﹤0.01% |
+541
| New | +$15.7K |
|
|
GMOV
8038
GMO US Value ETF
GMOV
$102M
| $15K | ﹤0.01% |
+615
| New | +$15.6K |
|
|
VIRX
8039
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $15K | ﹤0.01% |
93,177
+93,082
| +97,981% | +$18.3K |
|
8040
Alaunos Therapeutics
TCRT
$4.84M
| $15K | ﹤0.01% |
7,869
+6,841
| +665% | +$15.2K |
|
|
ZENV
8041
DELISTED
Zenvia
ZENV
| $15K | ﹤0.01% |
+6,430
| New | +$9.67K |
|
8042
JPMorgan ActiveBuilders Emerging Markets Equity ETF
JEMA
$1.67B
| $15K | ﹤0.01% |
+400
| New | +$15.8K |
|
8043
Crawford & Co Class B
CRD.B
$573M
| $14.9K | ﹤0.01% |
1,283
-1,785
| -58% | -$20.1K |
|
|
DOCT
8044
FT Vest US Equity Deep Buffer ETF October
DOCT
$387M
| $14.9K | ﹤0.01% |
378
-3,964
| -91% | -$156K |
|
|
BRIA
8045
BrilliA Inc
BRIA
$34.8M
| $14.9K | ﹤0.01% |
+3,900
| New | +$15.4K |
|
8046
TROOPS Inc
TROO
$243M
| $14.8K | ﹤0.01% |
+9,051
| New | +$18.5K |
|
|
AVX
8047
Avax One Technology Ltd
AVX
$25.4M
| $14.8K | ﹤0.01% |
58
+37
| +176% | +$17K |
|
8048
Virtus Biotech ETF
BBP
$96.7M
| $14.8K | ﹤0.01% |
+247
| New | +$15.6K |
|
8049
CALL
Vipshop
VIPS
$7.5B
| $14.8K | ﹤0.01% |
1,100
-96,018
| -99% | -$1.38M |
|
8050
Palisade Bio
PALI
$365M
| $14.8K | ﹤0.01% |
8,974
+8,943
| +28,848% | +$23.5K |
|
Similar funds
UBS Group's Q4 2024 Portfolio in Review
As of Q4 2024, UBS Group held 10,816 positions worth $541B, up 18% from $459B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
UBS Group deployed $80.6B of net new capital in Q4 2024, opening 1,380 new positions and adding to 6,046 existing holdings. Its largest new stake was Primo Brands: 1,234,826 shares worth $38M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was UnitedHealth, an estimated $561M trimmed.
- UBS Group's largest Q4 2024 buy was Primo Brands: 1,234,826 shares worth $38M.
- UBS Group added most to Strategy Inc in Q4 2024, an estimated $1.21B increase.
- UBS Group's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $561M.
- UBS Group fully exited CATALENT, INC. in Q4 2024, selling an estimated $86M.
- UBS Group's ten largest holdings make up 16% of its $541B portfolio in Q4 2024.
- UBS Group opened 1,380 new positions and closed 943 in Q4 2024.
- UBS Group's portfolio value rose 18% quarter-over-quarter to $541B.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.